JP7671244B2 - Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド - Google Patents

Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド Download PDF

Info

Publication number
JP7671244B2
JP7671244B2 JP2021519712A JP2021519712A JP7671244B2 JP 7671244 B2 JP7671244 B2 JP 7671244B2 JP 2021519712 A JP2021519712 A JP 2021519712A JP 2021519712 A JP2021519712 A JP 2021519712A JP 7671244 B2 JP7671244 B2 JP 7671244B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021519712A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020077255A5 (https=
JP2022504607A (ja
JP2022504607A5 (https=
Inventor
マリア ヘスス ブランコ－ピヤド，
フランセスコ ジー． サリトゥロ，
マーシャル リー モーニングスター，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2022504607A publication Critical patent/JP2022504607A/ja
Publication of JPWO2020077255A5 publication Critical patent/JPWO2020077255A5/ja
Publication of JP2022504607A5 publication Critical patent/JP2022504607A5/ja
Priority to JP2024020461A priority Critical patent/JP2024040444A/ja
Application granted granted Critical
Publication of JP7671244B2 publication Critical patent/JP7671244B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021519712A 2018-10-12 2019-10-11 Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド Active JP7671244B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024020461A JP2024040444A (ja) 2018-10-12 2024-02-14 Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862745109P 2018-10-12 2018-10-12
US62/745,109 2018-10-12
PCT/US2019/055926 WO2020077255A1 (en) 2018-10-12 2019-10-11 Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024020461A Division JP2024040444A (ja) 2018-10-12 2024-02-14 Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド

Publications (4)

Publication Number Publication Date
JP2022504607A JP2022504607A (ja) 2022-01-13
JPWO2020077255A5 JPWO2020077255A5 (https=) 2022-10-11
JP2022504607A5 JP2022504607A5 (https=) 2022-10-11
JP7671244B2 true JP7671244B2 (ja) 2025-05-01

Family

ID=68425315

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519712A Active JP7671244B2 (ja) 2018-10-12 2019-10-11 Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド
JP2024020461A Pending JP2024040444A (ja) 2018-10-12 2024-02-14 Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024020461A Pending JP2024040444A (ja) 2018-10-12 2024-02-14 Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド

Country Status (14)

Country Link
US (2) US11634453B2 (https=)
EP (2) EP4321519B1 (https=)
JP (2) JP7671244B2 (https=)
CN (2) CN113166193B (https=)
AR (1) AR116695A1 (https=)
AU (2) AU2019357040B2 (https=)
BR (1) BR112021009428A2 (https=)
CA (1) CA3115805A1 (https=)
DK (1) DK3864022T3 (https=)
ES (1) ES2966055T3 (https=)
IL (1) IL282183A (https=)
MX (2) MX2021004159A (https=)
TW (2) TWI835884B (https=)
WO (1) WO2020077255A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CN113166193B (zh) * 2018-10-12 2025-08-19 萨奇治疗股份有限公司 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531019A (ja) 2014-10-16 2017-10-19 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR100338287B1 (ko) * 1994-02-14 2002-11-30 푸르듀 파머 리미티드 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
FI972202L (fi) 1994-11-23 1997-07-17 Cocensys Inc Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
MX365644B (es) 2012-12-18 2019-06-10 Univ Washington Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos.
CN111741965B (zh) 2017-12-22 2024-06-25 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
EP3728284B1 (en) 2017-12-22 2024-08-21 Sage Therapeutics, Inc. 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
CN114656514B (zh) 2018-02-11 2024-05-14 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
CN113166193B (zh) * 2018-10-12 2025-08-19 萨奇治疗股份有限公司 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇
AU2020304673A1 (en) * 2019-06-27 2022-01-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US20230257415A1 (en) 2019-06-27 2023-08-17 Sage Therapeutics, Inc. Compounds for treating cns disorders
TW202143976A (zh) 2020-03-18 2021-12-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
IL299176A (en) 2020-06-24 2023-02-01 Sage Therapeutics Inc 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531019A (ja) 2014-10-16 2017-10-19 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VELEIRO,A.S. et al.，Structure-activity relationships of neuroactive steroids acting on the GABAA receptor，Current Medicinal Chemistry，2009年，Vol.16, No.4，p.455-472

Also Published As

Publication number Publication date
EP4321519A3 (en) 2024-05-01
TW202448479A (zh) 2024-12-16
EP3864022A1 (en) 2021-08-18
IL282183A (en) 2021-05-31
US20210340172A1 (en) 2021-11-04
US20240051987A1 (en) 2024-02-15
CN113166193A (zh) 2021-07-23
ES2966055T3 (es) 2024-04-18
EP4321519A2 (en) 2024-02-14
CN113166193B (zh) 2025-08-19
DK3864022T3 (da) 2023-12-18
JP2022504607A (ja) 2022-01-13
WO2020077255A1 (en) 2020-04-16
JP2024040444A (ja) 2024-03-25
MX2021004159A (es) 2021-09-08
US11634453B2 (en) 2023-04-25
AR116695A1 (es) 2021-06-02
AU2025200422A1 (en) 2025-02-13
US20240376144A9 (en) 2024-11-14
AU2019357040A1 (en) 2021-05-20
TWI835884B (zh) 2024-03-21
CA3115805A1 (en) 2020-04-16
EP4321519B1 (en) 2026-04-08
TWI886813B (zh) 2025-06-11
TW202027753A (zh) 2020-08-01
CN121045302A (zh) 2025-12-02
AU2019357040B2 (en) 2025-03-27
EP3864022B1 (en) 2023-09-20
BR112021009428A2 (pt) 2021-08-31
MX2024011494A (es) 2024-09-26

Similar Documents

Publication Publication Date Title
JP7611186B2 (ja) Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
JP7821842B2 (ja) Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
JP7671244B2 (ja) Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド
JP7817214B2 (ja) ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
JP6875996B2 (ja) 神経刺激性ステロイド、組成物、およびその使用
JP7692830B2 (ja) ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物
JP7817179B2 (ja) 神経刺激性ステロイド及びその使用方法
JP2025072521A (ja) Ｃｎｓ障害の処置のための組成物および方法
CN115850361B (zh) C7取代的氧固醇及其作为nmda调节剂的方法
JP7534291B2 (ja) ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法
WO2016123056A1 (en) Compositions and methods for treating cns disorders
JP2025060984A (ja) Ｃｎｓ障害を治療するための組成物及び方法
RU2796006C2 (ru) Нейроактивные стероиды, замещенные в положении 10 циклической группой, для использования при лечении расстройств цнс
HK40106568A (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
HK40059417B (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
HK40059417A (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250321

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250418

R150 Certificate of patent or registration of utility model

Ref document number: 7671244

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350